- Edwards Lifesciences (EW, Financial) reported a 6.2% increase in Q1 sales, reaching $1.41 billion.
- Transcatheter Mitral and Tricuspid Therapies (TMTT) sales soared 58%, totaling $115 million.
- Q1 earnings per share (EPS) were reported at $0.62; adjusted EPS was $0.64.
Edwards Lifesciences (EW) has announced its financial results for the first quarter ending March 31, 2025. The company reported a robust start to the year with Q1 sales increasing by 6.2% year-over-year to $1.41 billion, or 7.9% on an adjusted basis. Key drivers of this growth included the Transcatheter Aortic Valve Replacement (TAVR) sales, which grew by 3.8%, and the Transcatheter Mitral and Tricuspid Therapies (TMTT) sales, which surged by an impressive 58% to $115 million.
The company garnered attention with the recent CE Mark approval for its SAPIEN M3, enhancing its comprehensive TMTT portfolio. Furthermore, the National Coverage Determination (NCD) was finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE.
Edwards Lifesciences reaffirmed its 2025 guidance, expecting total sales to range between $5.7 to $6.1 billion and adjusted EPS of $2.40 to $2.50. The company expects continued growth in its TMTT segment, raising sales guidance for this segment to $530-$550 million. Despite pressures from tariffs and currency fluctuations, Edwards is optimistic about maintaining its operating margin guidance of 27% to 28%.
With cash and cash equivalents amounting to approximately $3.1 billion and total debt at $600 million, Edwards Lifesciences maintains a stable financial position. CEO Bernard Zovighian attributes the company's progress to its structural heart-focused strategy and its commitment to innovation, positioning Edwards for sustainable growth in the future.
